Bliss GVS Pharma: SEBI Takeover Regulation 31(4) Disclosure Filed

M&A / JV 24 Jun 2026 · Announced· ✓ Verified

Bliss GVS Pharma submitted a formal Regulation 31(4) disclosure to NSE, which is the mandatory post-acquisition statement when a party acquires shares triggering the takeover threshold. The disclosure triggers a 4-week window for the acquirer to make a public open offer for the remaining shares at the highest price paid. Without the acquirer identity and acquisition price in the filing header, the precise transaction structure cannot be confirmed from this alert alone.

Why it mattersA Regulation 31(4) disclosure (post-acquisition statement) indicates the acquirer has crossed a threshold (>25% or material stake) and must now comply with open-offer, dissemination and escrow requirements - material for tracking who is consolidating control in mid-cap pharma.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals